Viking Therapeutics, Inc. Stock News

SAN DIEGO, Jan. 5, 2026 /PRNewswire/ -- Viking Therapeutics, Inc. ("Viking") (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, today announced that its chief executive officer, Brian Lian, Ph.D., will deliver a corporate presentation at the 44th Annual J.P.

Novo Nordisk's wildly successful obesity medicine is now available as a pill, making it the first GLP-1 pill for weight loss in the U.S.

Viking Therapeutics remains a compelling obesity drugs contender, despite being in the pre-commercial phase. VKTX's dual-track pipeline (injectable and oral) and robust $700M liquidity position it well to enter the obesity drugs gold rush. Phase III results for VK2735 are critical in 2026 for VKTX's commercialization prospects and potential market share gains.

Viking Therapeutics is positioned favorably in the oral GLP-1 obesity drug race, with strong Phase 2 results for VK2735. VKTX's oral candidate achieved 12.2% weight loss at the highest dose in 13 weeks, matching or exceeding peers' metrics and showing potential for further improvement. Management will focus Phase 3 dosing on 20-75 mg, balancing efficacy and tolerability while the injectable 78-...

Viking Therapeutics has important catalysts on the horizon. Zoetis looks well-positioned to overcome recent challenges.

VKTX remains a Buy for its cheap FY2030 EV/Sales valuations of 2.28x, the strong clinical trial results exceeding legacy players, and the potential GLP-1 monetization upon US FDA approval. The management has also prudently focused on the oral/subcutaneous VK2735 clinical trials, potentially stretching their balance sheet over the next two years of unprofitability before requiring any capital ra...

A $1,000 investment can be an ideal amount to invest in an up-and-coming growth stock. The stocks below are still modest in size, with market capitalization of less than $6 billion.

Takeover activity has been high lately in the intensely competitive anti-obesity drug space. Viking's pipeline may contain plenty of hidden value that a larger company might release.